Introduction
Methods
Registry design
Outcome | Category |
---|---|
Clinical events | Stroke (ischaemic and haemorrhagic) |
Transient ischaemic attack | |
Peripheral/non-central nervous system embolism | |
Pulmonary embolism | |
Heart failure | |
Myocardial infarction | |
Hospitalization | |
Sudden cardiac death | |
Non-cardiovascular death | |
Bleeding events | |
Severity | Major |
Non-major clinically relevant | |
Minor | |
Location | Intracranial |
Ears, nose, throat | |
Gastrointestinal | |
Genitourinary | |
Vascular access site | |
Outcome | Recovered |
Permanently disabled | |
Fatal | |
Healthcare utilization used for bleeding event | Hospitalization |
Emergency room visit | |
Surgery for bleeding | |
Transfusion | |
Physician consultation | |
Therapy persistence | Rate of discontinuation |
Duration of time on therapy | |
Reasons for discontinuation | |
Hospitalization for any event | |
Any other hospital visits | Inpatient, outpatient, and emergency room |
Patients treated with vitamin K antagonists | Frequency and timing of monitoring |
INR recordings in relation to therapeutic range | |
Location of testing (self-monitoring, general practitioner clinic, anticoagulant clinic, etc.) | |
Dose adjustments | |
Use of bridging anticoagulation necessitated by interruption of vitamin-K antagonist | |
Outcomes in relation to INR fluctuation | |
Patients treated with additional antithrombotic therapy | Therapy changes (discontinuation, temporary interruptions and use of bridging therapy) |
Reasons of therapy changes (if applicable) | |
Patient treatment satisfaction using the Anti-Clot Treatment Scale (ACTS), depending on the cohort and country (at 4, 12, 24 months) |
Registry population and site selection
Data capture
Data management
Statistical analysis
Results
Baseline characteristics
Variable | All patients (N = 5072) |
---|---|
Agea, mean ± SD, years | 69.5 ± 11.0 |
Age groupa, n (%) | |
< 65 | 1444 (28.5) |
65–74 | 1861 (36.8) |
≥ 75 | 1758 (34.7) |
Women, n (%) | 2248 (44.3) |
Body mass indexb, mean ± SD, kg/m2 | 29.2 ± 5.7 |
Smoking status (current/previous)c, n (%) | 1599 (35.3) |
Pulsed, mean ± SD, bpm | 85.1 ± 23.8 |
Medical history, n (%) | |
Hypertensione | 3899 (77.0) |
Hypercholesterolemiaf | 2208 (43.9) |
Diabetes mellitusg | 1227 (24.3) |
Congestive heart failureh | 1086 (21.5) |
Family history of cardiac diseasei | 618 (19.5) |
Coronary artery diseasej | 967 (19.2) |
Current/History of myocardial infarction or unstable anginak | 718 (14.2) |
Chronic renal diseasel | |
Mild renal dysfunction (stage: I, II) | 629 (13.5) |
Moderate renal dysfunction (stage: III) | 186 (4.0) |
Severe renal dysfunction (stage: IV, V) | 26 (0.6) |
Left ventricular ejection fraction < 40%m | 305 (9.5) |
Stroken | 365 (7.2) |
Transient ischaemic attacko | 331 (6.5) |
Aortic or peripheral artery diseasep | 252 (5.0) |
Carotid diseaseq | 212 (4.2) |
History of bleedingr | 118 (2.3) |
Heavy alcohol consumptions | 83 (2.1) |
Venous thromboembolismt | 103 (2.0) |
Systemic embolizationu | 56 (1.1) |
Cirrhosisv | 20 (0.4) |
Rivaroxaban dosing
Concomitant antiplatelet therapy
Antiplatelet druga | All patients (N = 5072) | Patients with CHA2DS2-VASc score of 0 or 1 (N = 665) | Patients with CHA2DS2-VASc score 2–9 (N = 4289) |
---|---|---|---|
Acetylsalicylic acid (Aspirin/ASA) | 501 (9.9) | 28 (4.2) | 465 (10.8) |
ADP receptor/P2Y12 inhibitor | 248 (4.9) | 13 (2.0) | 231 (5.4) |
Glycoprotein IIb/IIIa inhibitor | 9 (0.2) | 2 (0.3) | 6 (0.1) |
Prostaglandin analogue | 71 (1.4) | 5 (0.8) | 66 (1.5) |
Other antiplatelet | 8 (0.2) | 2 (0.3) | 6 (0.1) |
Discussion
RIVER | XANTUS | EXPAND | XAPASS | |
---|---|---|---|---|
Patients, n | 5072 | 6784 | 7141 | 11,308 |
Patient characteristics | ||||
Sex, male (%) | 55.7 | 59.2 | 67.7 | 61.9 |
Age, mean (SD) | 69.5 (11.0) | 71.5 (10.0) | 71.6 (9.4) | 73.1 (9.9) |
BMI (Kg/m2), mean (SD) | 29.2 (5.7) | 28.3 (5.0) | NA | 23.7 (3.8) |
Creatinine clearance (mL/min), mean (SD) | 83.7 (35.6) | NA | 69.7 (26.2) | 67.7 (28.9) |
< 15 mL/min (%) | 0.02 | 0.3 | NA | 0.03 |
≥ 15 to < 30 mL/min (%) | 0.7 | 1.1 | 1.9 | 2.8 |
≥ 30 to < 50 mL/min (%) | 7.9 | 8.0 | 18.9 | 21.1 |
≥ 50 mL/min (%) | 53.4 | 56.2 | 74.6 | 68.0 |
Missing (%) | 38.0 | 34.4 | 4.7 | 8.2 |
Rivaroxaban dose/dosing frequency | ||||
10 mg once daily | 105 (2.1) | NA | NA | NA |
15 mg once daily | 1008 (20.0) | 1410 (20.8) | NA | NA |
20 mg once daily | 3867 (76.5) | 5336 (78.7) | NA | NA |
10 mg twice daily | 10 (0.2) | NA | NA | NA |
15 mg twice daily | 29 (0.6) | NA | NA | NA |
20 mg twice daily | 22 (0.4) | NA | NA | NA |
10/15/20 mg other dosing Regimen | 12 (0.2) | 35 (0.5) | NA | NA |
CHADS2 score, mean (SD) | 1.9 (1.2) | 2.0 (1.3) | 2.1 (1.3) | 2.2 (1.3) |
CHA2DS2-VASc score, mean (SD) | 3.2 (1.6) | 3.4 (1.7) | 3.4 (1.7) | NA |
Comorbidity/medical history | ||||
Congestive heart failure (%) | 21.5 | 18.6 | 26.1 | 25.0 |
Hypertension (%) | 77.0 | 74.7 | 70.9 | 74.3 |
Diabetes mellitus (%) | 24.3 | 19.6 | 24.3 | 22.3 |
History of stroke/systemic embolism/TIA (%) | 13.4 | 19.0 | 24.1 | 23.7 |
Type of AF | ||||
Paroxysmal (%) | 34.2 | 40.7 | 44.8 | NA |
Non-paroxysmal (persistent/permanent) (%) | 31.6 | 40.8 | 55.2 | NA |
First diagnosed (%) | 34.2 | 18.5 | NA | NA |